2026年11月3日星期二
M
Всеобъемлющее обозрение
Глобальные новости
Oriental Kopi founder wants to put Malaysia on the menu— 日经 Nikkei AsiaIndonesian political maneuvers hinder market reforms amid downgrade threats— 日经 Nikkei AsiaChinese Communist Party taps big data surveillance to combat corruption— 日经 Nikkei AsiaJapan is attracting startups. But can it keep them?— 日经 Nikkei AsiaMitsubishi Heavy gears up to boost US gas turbine production— 日经 Nikkei AsiaNuclear reactors under construction rise to 79 globally on AI demand— 日经 Nikkei AsiaMyanmar refugees fill labor gaps in Thailand as Cambodians return home— 日经 Nikkei AsiaCyber insurance inquiries surge at Japan's nonlife insurers— 日经 Nikkei AsiaOriental Kopi founder wants to put Malaysia on the menu— 日经 Nikkei AsiaIndonesian political maneuvers hinder market reforms amid downgrade threats— 日经 Nikkei AsiaChinese Communist Party taps big data surveillance to combat corruption— 日经 Nikkei AsiaJapan is attracting startups. But can it keep them?— 日经 Nikkei AsiaMitsubishi Heavy gears up to boost US gas turbine production— 日经 Nikkei AsiaNuclear reactors under construction rise to 79 globally on AI demand— 日经 Nikkei AsiaMyanmar refugees fill labor gaps in Thailand as Cambodians return home— 日经 Nikkei AsiaCyber insurance inquiries surge at Japan's nonlife insurers— 日经 Nikkei Asia

Povorcitinib for nonsegmental vitiligo: two randomized, controlled, phase 3 STOP-V trials

Источник Nature 医学研究21 часов назад
Аннотация

Сайт предоставляет только заголовки и индексы аннотаций; полный контент и авторские права принадлежат первоисточнику. Для чтения перейдите по ссылке на оригинал.

Перейти к оригиналу
Канал
Здоровье
Регион
Глобальный взгляд
Язык оригинала
English
Номер записи
health-00a74bed

Comments 0 comments

No comments yet. Be the first.

Povorcitinib for nonsegmental vitiligo: two randomized, controlled, phase 3 STOP-V trials · Всеобъемлющее обозрение